Provided herein are methods, compounds, and compositions for reducing expression of transthyretin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate transthyretin amyloidosis, or a symptom thereof.

Provided are novel compounds of Formula (I): ##STR00001##
pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORγ. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.

Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described.

Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP). Such methods, compounds, and composition are useful to treat, prevent, or ameliorate diseases, including neurodegenerative diseases, such as Huntington's Disease (HD).

The invention relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the ALAS1 gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of ALAS1.

The present invention addresses the problem of providing a novel composition having the effect of improving a mental state. The present invention pertains to: a composition that is for improving a mental state, and that contains, as an active ingredient, a water-soluble component of the fruit of eggplant (Solanum melongena); and a production method that is for an eggplant-derived composition for improving a mental state, and that comprises squeezing an eggplant fruit to obtain a juice, or adding water to an eggplant fruit and squeezing the fruit to which water has been added, to obtain a juice.

The present invention addresses the problem of providing a novel composition having the effect of improving a mental state. The present invention pertains to: a composition that is for improving a mental state, and that contains, as an active ingredient, a water-soluble component of the fruit of eggplant (Solanum melongena); and a production method that is for an eggplant-derived composition for improving a mental state, and that comprises squeezing an eggplant fruit to obtain a juice, or adding water to an eggplant fruit and squeezing the fruit to which water has been added, to obtain a juice.

Various aspects of this patent document relate to methods of administering cannabinoid anions to treat various health conditions.

Various aspects of this patent document relate to methods of administering cannabinoid anions to treat various health conditions.

This disclosure provides compounds and compositions which may be modulators of MAGL and/or ABHD6 and their use as medicinal agents, processes for their preparation, and pharmaceutical compositions that include disclosed compounds as at least one active agent. The disclosure also provides for method of treating a patient in need thereof, where the patient is suffering from post-traumatic stress disorder comprising administering a disclosed compound or composition.